DURAVYU™ (vorolanib intravitreal insert)

Why Do Real-World Wet AMD Outcomes Differ From Those Seen in Clinical Trials?

Sophie Bakri, MD; Durga S. Borkar, MD, MMCi; and Jayanth Sridhar, MD

Show Description +

Durga S. Borkar, MD, MMCi, and Jayanth Sridhar, MD, highlight why visual acuity outcomes in the real world differ from those in clinical trials and why a new class of treatment for wet age-related macular degeneration and diabetic macular edema is needed.

Posted: 5/16/2025

Keywords:

Wet AMD

•

Age-Related Macular Degeneration (AMD)

•

Clinical Trials

•

EyePoint Pharmaceuticals

•

EYP-1901

•

TKI

•

tyrosine-kinase inhibitor

•

vorolanib

•

DURAVYU

•

An overview of TKIs and how they may fit into the wAMD treatment regimen

Up Next

Name: Why Do Real-World Wet AMD Outcomes Differ From Those Seen in Clinical Trials?
Uploaded: 2025-05-16T20:34:24+00:00
Description: Durga S. Borkar, MD, MMCi, and Jayanth Sridhar, MD, highlight why visual acuity outcomes in the real world differ from those in clinical trials and why a new class of treatment for wet age-related macular degeneration and diabetic macular edema is needed.

Wet AMD and DME Therapy in Development

Sophie Bakri, MD; Durga S. Borkar, MD, MMCi; and Jayanth Sridhar, MD

An overview of TKIs and how they may fit into the wAMD treatment regimen

Why Do Real-World Wet AMD Outcomes Differ From Those Seen in Clinical Trials?

Sophie Bakri, MD; Durga S. Borkar, MD, MMCi; and Jayanth Sridhar, MD

Wet AMD and DME Therapy in Development

Sophie Bakri, MD; Durga S. Borkar, MD, MMCi; and Jayanth Sridhar, MD

TKIs: How Do They Work?

Sophie Bakri, MD; Durga S. Borkar, MD, MMCi; and Jayanth Sridhar, MD

What is EYP-1901 (DURAVYU™, (vorolanib intravitreal insert))?

Sophie Bakri, MD; Durga S. Borkar, MD, MMCi; and Jayanth Sridhar, MD

What Evidence Makes EYP-1901 a Promising Treatment for Wet AMD and DME?

Sophie Bakri, MD; Ehsan Rahimy, MD; and Lejla Vajzovic, MD

How Can a Multi-MOA Approach Benefit the Management of Wet AMD?

Sophie Bakri, MD; Ehsan Rahimy, MD; and Lejla Vajzovic, MD

How May Tolerance for Subretinal Fluid Change Given Sustained-Release EYP-1901?

Sophie Bakri, MD; Ehsan Rahimy, MD; and Lejla Vajzovic, MD

Reinjection Criteria

Sophie Bakri, MD; Ehsan Rahimy, MD; and Lejla Vajzovic, MD

Patient Selection for EYP-1901

Sophie Bakri, MD; Ehsan Rahimy, MD; and Lejla Vajzovic, MD

Additional Videos

EYP1901 Mechanism of Action

Back to All Videos

Why Do Real-World Wet AMD Outcomes Differ From Those Seen in Clinical Trials?

Sophie Bakri, MD; Durga S. Borkar, MD, MMCi; and Jayanth Sridhar, MD

Durga S. Borkar, MD, MMCi, and Jayanth Sridhar, MD, highlight why visual acuity outcomes in the real world differ from those in clinical trials and why a new class of treatment for wet age-related macular degeneration and diabetic macular edema is needed.

Posted: 5/16/2025

Keywords:

Wet AMD

•

Age-Related Macular Degeneration (AMD)

•

Clinical Trials

•

EyePoint Pharmaceuticals

•

EYP-1901

•

TKI

•

tyrosine-kinase inhibitor

•

vorolanib

•

DURAVYU

•

An overview of TKIs and how they may fit into the wAMD treatment regimen

Resources

Addressing the Gaps in Duration of Treatment for Age-Related Macular Degeneration

View Resource

Scientific Publications

View Resource

Image Gallery

About EyePoint Pharmaceuticals

EyePoint is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. The Company’s lead product candidate, DURAVYU™ is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E™.

Visit us online: eyepointpharma.com

Follow EyePoint Pharmaceuticals

DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU™ is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

DURAVYU (EYP-1901), is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E™ - efficacy and safety have not yet been established with well controlled, phase 3 pivotal trials.